Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19585871 | 0.83 | CRBN (0.71) | CRBNDDB1HTTPOLBKMT2A | |
| SCHEMBL11627271 | 0.83 | GLA (0.64) | GLAFFAR1CRBNDDB1HTT | |
| SCHEMBL29158181 | 0.83 | FFAR1 (0.65) | GLAFFAR1CRBNDDB1HTT | |
| SCHEMBL11270285 | 0.83 | GLA (0.60) | GLAFFAR1CRBNDDB1HTT | |
| SCHEMBL29049309 | 0.83 | FFAR1 (0.65) | GLAFFAR1CRBNDDB1HTT | |
| SCHEMBL31139945 | 0.83 | GLA (0.60) | GLAFFAR1CRBNDDB1HTT | |
| SCHEMBL7268381 | 0.82 | CRBN (0.70) | GLAFFAR1CRBNDDB1HTT | |
| SCHEMBL28411469 | 0.79 | GLA (0.56) | GLAFFAR1CRBNDDB1HTT | |
| SCHEMBL11629119 | 0.79 | GLA (0.59) | GLAFFAR1CRBNDDB1HTT | |
| Bicarbonate SCHEMBL29264497 | 0.78 | CRBN (0.64) | GLAFFAR1CRBNDDB1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211724-A1 | Hiv integrase inhibitors | VERSCHUEREN GASTON W | 2006-09-21 | — | — | US | disclosed |
| CN-1812992-A | HIV integrase inhibitors | TIBOTEC PHARM LTD (IE) | 2006-08-02 | — | — | CN | disclosed |
| EP-1625130-A2 | HIV INTEGRASE INHIBITORS | Tibotec Pharmaceuticals Ltd. (IE) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004096807-A2 | HIV INTEGRASE INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211724-A1 | Hiv integrase inhibitors | SULT1A1, SULT2A1, SULT1E1 | GLA 3463/4885FFAR1 672/4885CRBN 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.